Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.38 USD | -1.14% | -5.64% | +29.91% |
06-11 | Irish banks can absorb commercial real estate price shock, regulator says | RE |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 6.98 and 7.26 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.91% | 13.01B | - | ||
+15.81% | 566B | C+ | ||
+18.77% | 313B | C+ | ||
+19.11% | 251B | C+ | ||
+24.95% | 182B | B- | ||
+31.54% | 170B | B- | ||
+9.05% | 160B | C+ | ||
+5.56% | 147B | B- | ||
-3.01% | 147B | B- | ||
+13.54% | 142B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A5G Stock
- AIBGY Stock
- Ratings AIB Group plc